Neogenomics Inc
NASDAQ:NEO

Watchlist Manager
Neogenomics Inc Logo
Neogenomics Inc
NASDAQ:NEO
Watchlist
Price: 16.39 USD 6.5% Market Closed
Market Cap: 2.1B USD
Have any thoughts about
Neogenomics Inc?
Write Note

Gross Margin
Neogenomics Inc

43.5%
Current
40%
Average
43.8%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
43.5%
=
Gross Profit
280.4m
/
Revenue
644.1m

Gross Margin Across Competitors

Country US
Market Cap 2.1B USD
Gross Margin
44%
Country US
Market Cap 1.3T USD
Gross Margin
55%
Country US
Market Cap 196.3B USD
Gross Margin
41%
Country US
Market Cap 170.3B USD
Gross Margin
60%
Country KR
Market Cap 66.5T KRW
Gross Margin
50%
Country CH
Market Cap 37.6B CHF
Gross Margin
29%
Country US
Market Cap 38.5B USD
Gross Margin
55%
Country US
Market Cap 36.7B USD
Gross Margin
35%
Country US
Market Cap 26.4B USD
Gross Margin
59%
Country US
Market Cap 23B USD
Gross Margin
35%
Country US
Market Cap 22.3B USD
Gross Margin
64%
No Stocks Found

Neogenomics Inc
Glance View

Market Cap
2.1B USD
Industry
Life Sciences Tools & Services

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,000 full-time employees. The company went IPO on 2012-12-10. The firm operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. The company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. The company operates testing laboratories in United States, Europe and Asia.

NEO Intrinsic Value
12.26 USD
Overvaluation 25%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
43.5%
=
Gross Profit
280.4m
/
Revenue
644.1m
What is the Gross Margin of Neogenomics Inc?

Based on Neogenomics Inc's most recent financial statements, the company has Gross Margin of 43.5%.